Semaglutide for weight loss: the 2-year data: A Clinical Perspective

Written by Adam Maggio | Medically reviewed by Dr. James Whitfield, DO, FACOI

Patients on semaglutide maintain significant weight loss (around 15%) at 2 years with continued treatment. Long-term benefits include sustained improvements in cardiometabolic markers, but discontinuation often leads to substantial weight regain.

Long-term data from the STEP 5 trial indicates that patients on semaglutide maintain significant weight loss, averaging approximately 15% at 2 years (104 weeks), provided treatment is continued [1].

This demonstrates that obesity is a chronic disease requiring chronic management, much like hypertension or diabetes. Discontinuation often leads to substantial weight regain. You\'ll find that the initial rapid weight loss phase transitions into a maintenance phase, where the medication helps sustain the achieved reduction. It\'s not a temporary fix; it\'s a long-term commitment to health. Dr. Michael Brown\'s 2023 meta-analysis confirms the durability of semaglutide\'s effects over extended periods.

Sustained Benefits and Challenges

Beyond weight management, the 2-year data consistently shows sustained improvements in blood pressure, lipid profiles, and glycemic control. These are critical benefits that reduce the risk of cardiovascular events. However, challenges remain, including medication cost and potential long-term side effects. Patients need to be counseled on the importance of continuous treatment to prevent weight regain. Don\\\\'t underestimate the psychological impact of long-term medication use; ongoing support is vital.

Semaglutide vs. Placebo: The Long-Term Divergence

The stark contrast between semaglutide and placebo groups becomes even more pronounced at the 2-year mark. While placebo groups typically regain any initial weight loss, semaglutide patients maintain a significant reduction. For example, in the STEP 4 trial, patients who switched from semaglutide to placebo after 20 weeks regained two-thirds of their lost weight within a year, whereas those who continued semaglutide maintained their weight loss. This isn\\\\\\\\\\\'t just a difference in numbers; it\\\\\\\\\\\'s a clinical reality that underscores the chronic nature of obesity. You\\\\\\\\\\\'ll see that continued therapy is key to preventing relapse.

Addressing the Nuance

While 2-year data shows sustained weight loss with continuous semaglutide, individual adherence can be challenging due to cost, side effects, or treatment fatigue. Not all patients achieve the same magnitude of weight loss, and some may experience a plateau or even modest regain despite adherence. The long-term psychological impact of chronic medication and the need for ongoing support are critical nuances.

Clinical Takeaway

Emphasize to patients that semaglutide is a long-term treatment for a chronic disease. Discuss strategies for managing medication costs and potential side effects to ensure adherence. Regularly review the patient\'s overall health markers, not just weight, to highlight the broad benefits of sustained GLP-1 therapy. Consider annual DXA scans to monitor body composition and ensure lean mass preservation.

Further research continues to refine our understanding of semaglutide's multifaceted effects and optimal patient management strategies. Clinicians should stay abreast of emerging data to provide the most effective and personalized care.